Ascendis Pharma A/S

Ascendis Pharma A/S P/B

The P/B (Price-to-Book Ratio) of Ascendis Pharma A/S (ASND) as of Nov 5, 2026 is -58.94. In the previous year, P/B (Price-to-Book Ratio) was -90.75 — a change of -35.05% (higher).

P/B

-58.94

YoY

-35.05%

Last updated:

P/B (Price-to-Book Ratio) of Ascendis Pharma A/S is 2025 -58.94 . P/B (Price-to-Book Ratio) of Ascendis Pharma A/S was 2024 -90.75 . It decreases by -35.05% higher compared to the previous year.

The Ascendis Pharma A/S P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
34.25 EUR
Jan 1, 2019
16.06 EUR
Jan 1, 2020
11.44 EUR
Jan 1, 2021
10.86 EUR
Jan 1, 2022
36.43 EUR
Jan 1, 2023
-65.84 EUR
Jan 1, 2024
-90.75 EUR
Jan 1, 2025
-58.94 EUR
The Ascendis Pharma A/S P/B history
YEARP/BYoY
-58.94-35.05%
-90.75+37.83%
-65.84-280.75%
36.43+235.54%
10.86-5.08%
11.44-28.81%
16.06-53.10%
34.25-33.15%
51.24-5.66%
54.31-31.87%
79.72-61.93%
209.40—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Ascendis Pharma A/S Stock analysis

What does Ascendis Pharma A/S do? Ascendis Pharma A/S is a biopharmaceutical company based in Denmark that focuses on developing innovative therapies for diseases that currently have no suitable treatment options. The company was founded in 2007 and is headquartered in Hellerup, Denmark. History The company was founded by an experienced team of researchers and professionals from the pharmaceutical and biotech industry who recognized the need for new therapies for chronic diseases. They used innovative technologies to develop drugs that would have longer-lasting effects, thus reducing the need for frequent doses. In 2015, the company went public to raise additional capital for the further development of their technologies and products. Business model Ascendis Pharma A/S is working on the development of drugs using a proprietary technology platform called TransCon technology. TransCon technology is a novel delivery system that allows drugs to remain in the body for longer periods of time, thus achieving a continuous effect. This leads to a reduced need for frequent doses, improving patient care and adherence to therapy. The company follows an asset-based business model strategy. It aims to market its products globally through a licensing and partnering approach. By partnering with established pharmaceutical companies, Ascendis Pharma A/S can introduce their drugs into broader markets while ensuring resources for further research and development. Divisions Ascendis Pharma A/S has two main business divisions: 1. Endocrinology: Ascendis Pharma A/S is a leader in the development of therapies for diseases caused by hormonal disorders. The TransCon technology is used for the delivery of hormones such as growth hormone, parathyroid hormone, follicle-stimulating hormone, and luteinizing hormone to achieve continuous release in the body. 2. Oncology: The company also utilizes the TransCon technology for the delivery of cytokines for cancer immunotherapy. Products The most well-known product of Ascendis Pharma A/S is TransCon Growth Hormone, a growth hormone therapy that has longer-lasting effects and only needs to be administered once a week for children with growth hormone deficiency. The company also has TransCon PTH and TransCon CNP in the endocrinology pipeline. In oncology, the company has developed TransCon IL-2, an interleukin-2 immunotherapy for cancer. Summary Ascendis Pharma A/S is an innovative biopharmaceutical company specializing in the development of therapies for chronic diseases. The company utilizes its proprietary technology platform, TransCon technology, to develop drugs that have longer-lasting effects and reduce the need for frequent doses. It focuses on endocrinology and oncology and follows an asset-based business model strategy by entering partnerships with established pharmaceutical companies. The most well-known product of Ascendis Pharma A/S is TransCon Growth Hormone. Ascendis Pharma A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ascendis Pharma A/S stock

P/B (Price-to-Book Ratio) of Ascendis Pharma A/S is -58.94 in 2025.

P/B (Price-to-Book Ratio) of Ascendis Pharma A/S changed from -90.75 to -58.94, representing a -35.05% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) Ascendis Pharma A/S since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s Ascendis Pharma A/S with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Valuation — Ascendis Pharma A/S

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Ascendis Pharma A/S